• Exploring how integrating antibody engineering with radioligand design enables precise delivery of therapeutic isotopes to immune-relevant tumor environments
• Showcasing how emerging immune-regulatory targets beyond PD-(L)1 offer novel pathways for targeted radioligand modulation
• Analyzing tumor-restricted glycoproteins as highly specific anchors for next-generation theranostic development

New Company for 2026